ADR-001 is under clinical development by Rohto Pharmaceutical and currently in Phase I for IgA Nephropathy (Berger’s Disease). According to GlobalData, Phase I drugs for IgA Nephropathy (Berger’s Disease) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADR-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADR-001 overview
ADR-001 is under development for the treatment of IgA nephropathy, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), pneumonia, liver cirrhosis (compensated and decompensated cirrhosis), idiopathic peripheral corneal ulcer and cGVHD related corneal ulcer and idiopathic pulmonary fibrosis. The drug candidate consists of bamboo adipose-derived mesenchymal stem cells. It is administered by intravenous and subconjunctival route.
Rohto Pharmaceutical overview
Rohto Pharmaceutical is engaged in manufacturing and marketing of pharmaceutical products, cosmetics and functional foods. The company offers products for eye care, skincare, internal medicine and other diseases. Under eyecare products, the company offers eye drops, contact lenses and eyewash. Under skincare products, the company offers face wash, creams, lotions, medicine and medicated products. It also offers medicines for internal use such as digestive products and herbal medicines. It has manufacturing and research laboratories in Iga, Osaka and Kyoto. The company along with its subsidiaries operates across the Americas, Asia, Japan, Oceania, Africa and Europe. Rohto Pharmaceutical is headquartered in Osaka, Japan.
For a complete picture of ADR-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
